60 Degrees Pharmaceuticals (NASDAQ: SXTP) might be one of the most overlooked micro-cap opportunities in the biotech space right now. We sat down with CEO Dr. Geoffrey Dow to uncover what most retail investors are completely missing an FDA-approved drug already generating revenue, a 100% cure rate in their babesiosis trial, and zero approved competition in a market worth over a billion dollars. With only about 1.3 million shares outstanding after their recent reverse split, this stock doesn’t need much fuel to move fast.
Our analyst coverage puts a price target on SXTP and when you look at the clinical data, the Yale and Mount Sinai partnerships, the 223% revenue growth, and a CEO who keeps buying his own stock, that target starts to look conservative. Watch the full Marathon Money interview with Dr. Dow, then do your own research because the window on this one may not stay open long.
Full Buying Report is below in the box
Join Now Log In
Listen to the Free Version of Marathon Money
This content is provided by Marathon Money for informational and educational entertainment purposes only. Nothing discussed in this interview should be considered financial, investment, legal, or tax advice.
The views and opinions expressed by guests are their own and do not necessarily reflect those of Marathon Money. Investing in stocks and other financial instruments involves risk, including the potential loss of principal.
Viewers and listeners should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
Marathon Money does not make any guarantees regarding the accuracy, completeness, or timeliness of the information presented.
Podcast: Play in new window | Download
Discover more from Marathon Money +
Subscribe to get the latest posts sent to your email.